WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc.

March 09, 2005 09:00 ET

Wex Pharmaceuticals Inc.: Appointment of Chief Medical Officer


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: WEX PHARMACEUTICALS INC.

TSX SYMBOL: WXI

MARCH 9, 2005 - 09:00 ET

Wex Pharmaceuticals Inc.: Appointment of Chief Medical
Officer

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 9, 2005) - WEX
Pharmaceuticals Inc. "WEX" (TSX:WXI) is pleased to announce the
appointment of Dr. Jean Bourgouin as its new Chief Medical Officer in
charge of all clinical, non-clinical and discovery programs.

Dr. Jean Bourgouin brings to WEX over 25 years experience in global
clinical drug development within the pharmaceutical industry in a wide
range of clinical and project leadership positions. He joined the
Rhone-Poulenc Rorer organization in Canada in 1982 as project leader in
the Medical department. Throughout the 1980s and into the 1990s, he held
positions of increasing responsibilities, becoming Director, Clinical
Research in 1985 and Vice President, Research and Development in 1988.
In 1996, he was named Vice President of the company's Specialties
Division, where he oversaw marketing, sales and strategic clinical
development for hospital products.

In 1997, Dr. Bourgouin joined the Hoechst Marion Roussel organization as
Executive Vice President Scientific Affairs. When the global Hoechst and
Rhone-Poulenc organizations merged to form Aventis in 1999, he took the
role of Vice President, Scientific Affairs with responsibilities of all
stages of clinical development in Canada as well as registration and
market access using health economics, health management and professional
education strategies.

"We are delighted to welcome Dr. Jean Bourgouin to our management team,"
said Frank Shum, President and CEO of WEX. "His extensive clinical
experience in the industry and extraordinary leadership skills will be
of essence for building successful clinical programs for our company."

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is a neuro bio-science company dedicated to the
discovery of new therapeutic agents for the treatment of moderate to
severe pain, symptom relief associated with addiction withdrawal from
opioid abuse, and medicines designed for local and regional anaesthesia.
The Company's principle business strategy is to derive drugs from
naturally occurring toxins and develop proprietary products for the
Global market. The Company's Chinese subsidiary sells generic products
manufactured at its facility in China and are expanding its marketing
efforts in the rest of Asia.


-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    WEX Pharmaceuticals Inc.
    Don Evans
    Corporate Communications
    (604) 683-8880 or Toll Free: 1-800-722-7549
    (604) 683-8868 (FAX)
    or
    WEX Pharmaceuticals Inc.
    Gordon Stanley
    Corporate Communications
    (604) 683-8880 or Toll Free: 1-800-722-7549
    (604) 683-8868 (FAX)
    wex@wexpharma.com
    www.wexpharma.com